S.Res. 97
A resolution expressing the sense of the Senate that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.
Referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S2654)
Sponsor
Sen. Coburn, Tom [R-OK]
Bill Details
- Update Date
- Nov 15, 2022
- Origin Chamber
- Senate
- Bill Type
- SRES
- Resolution Number
- 97
- Congress
- 113
- Introduced Date
- Apr 15, 2013
- Policy Area
- Health
- Is Law
- No
Referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S2654)
Source: Senate
Introduced in Senate
Source: Library of Congress
Expresses the sense of the Senate that the Food and Drug Administration (FDA) should exercise its acknowledged authority to: (1) refuse to approve generic versions of non-abuse-deterrent opioid products that have been replaced in the market with abuse-deterrent formulations recognized by FDA as effective, and (2) require generic versions of abuse-deterrent opioid products to be formulated with comparable abuse-deterrent features.
Health, Education, Labor, and Pensions Committee
Introduced in Senate
Apr 15, 2013